Twelve to twenty-two sessions a year. That's how much behavioral therapy federal workers will be expected to log in 2027 if they want their plan to keep paying for a weight-loss GLP-1. You're listening to GLP-1 Daily. On this Tuesday's rundown: new strings on federal employee coverage, a diabetes consensus report that moves GLP-1s toward the front of the line, a pill that skips the fasting rules, a fresh look at where semaglutide's heart benefit comes from, and the youngest patients on these drugs. Hit follow and you won't have to come looking for the next episode.
Ian Smith, writing for FedSmith:
Federal employees and retirees who take weight loss drugs through their health plans will face a new requirement in 2027: documented participation in an intensive behavioral therapy program. It is one of several changes the Office of Personnel Management (OPM) outlined in its Open Season highlights for the 2027 plan year.
Notice the wording. Before treatment and during it. So this isn't only about new starts. If you're a federal employee or retiree already on one of these drugs through your plan, it reaches you too. What stays the same: federal and postal plans still have to cover at least one GLP-1 anti-obesity medication and at least two oral ones. What's new is the paperwork. Plans are expected to cover twelve to twenty-two therapy sessions a year, depending on progress, plus medical nutrition therapy. There's a children's piece too. Plans must cover behavioral programs for kids six and older with a BMI above the ninety-fifth percentile, twenty-six or more contact hours over three to twelve months. Generous on paper. But who has twenty-six spare hours and a program nearby? A requirement like this is only fair if the sessions actually exist where people live. The cost backdrop. OPM has named GLP-1s as one driver of rising premiums, and the enrollee share goes up an average of ten point nine percent in 2027. A December 2025 inspector general report found GLP-1 pharmacy spending up more than five hundred percent from 2019 to 2024 at the two carriers it studied. Open Season runs November ninth through December fourteenth, and full plan brochures go up on OPM's website in early November. If you're on one of these medications, read how your plan applies the rule, and bring your prescriber in early so missing documentation doesn't become the reason a refill stalls.
Peptide News Digest, in a patient's guide to the new joint report from the American Diabetes Association and the European Association for the Study of Diabetes:
The key sentence says most people with type 2 diabetes "would benefit from early introduction of an SGLT2 inhibitor or/and GLP-1-based therapy, potentially from diagnosis." The report calls both families "first-line therapeutic considerations" and says their heart benefits do not depend on metformin.
It came out October second in Diabetes Care and Diabetologia, the first joint report since 2022. And the title lost a word. Hyperglycemia is gone. Blood sugar is no longer the whole frame; heart, kidneys and liver are in it now. Weight gets equal billing as well. The report says weight targets, achieved by any means, are as essential as glucose targets. Now the caveats. Metformin isn't thrown out. The authors say the evidence that newer drugs work regardless of metformin comes from subgroup analyses not protected by randomisation. Many of the authors, both chairs included, list paid consulting or advisory work for Lilly and Novo Nordisk. The ADA and EASD paid for the work itself. And read the cost column. The report's own drug table rates metformin as low cost and both newer families as high. A guideline saying potentially from diagnosis doesn't approve a single prior auth. The guide cites a survey where sixty percent of U.S. employers cover GLP-1s for diabetes only. Fine if your chart has the diabetes code. Everyone without one is still outside the door. The report has no legal force; your plan still decides what it pays for. But if you have type 2 diabetes, it's fair to ask your clinician whether your heart and kidney risk makes an SGLT2 inhibitor, a GLP-1-based drug, or both worth discussing now rather than later.
Lixin Guo and colleagues, writing in Nature Medicine:
Safiglipron is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered without fasting or dietary restrictions. We evaluated its efficacy and safety versus dapagliflozin in OUTSTAND-2, a phase 3, multicenter, randomized, double-blind, double-dummy, active-comparator-controlled trial conducted at 98 sites in China.
Translation: a pill, a small molecule like Lilly's Foundayo rather than a peptide. The existing semaglutide pill has to be taken fasting with restricted water. This one doesn't. Eight hundred ten adults whose type 2 diabetes wasn't controlled on metformin, thirty-two weeks, against dapagliflozin, the SGLT2 pill. All three doses were non-inferior on A1C. Under the treatment policy estimand, only the top ninety-milligram dose met the bar for superiority. The sixty-milligram dose didn't. Hitting an A1C under seven: roughly fifty-five to sixty-four percent on safiglipron versus thirty-six and a half on dapagliflozin. Weight was a near tie, though. About four percent lost on the top dose, three point six on dapagliflozin. And then the stomach, as usual. GI side effects were more frequent on safiglipron, mostly mild or moderate, and about four percent stopped over adverse events versus one and a half percent on the comparator. It's peer-reviewed and double-blind, every site was in China, and the abstract doesn't name a funder. This one is investigational. Nobody's prescribing it here. Still, two first-line families from that consensus report, finally in the same ring.
Jerome Smail, writing in The Pharmacist:
However, the analysis found changes in the measured risk factors could explain no more than half of the reduction in serious cardiovascular events, including heart attack, stroke and cardiovascular death.
This is a new look at the SELECT trial, published in the European Heart Journal. Seventeen thousand six hundred four people with overweight or obesity and no diabetes. The original trial found a twenty percent lower risk of serious cardiovascular disease on semaglutide. The researchers followed two years of weight, waist, blood pressure, cholesterol, inflammation and kidney markers. Combined, they explained half the benefit at most. Lead author Helen Colhoun of the University of Edinburgh says semaglutide should be considered a cardiovascular disease reduction drug and not just a weight loss drug. That sentence matters for coverage fights. Plans keep filing these drugs under lifestyle. A heart benefit that isn't fully explained by the scale is a lot harder to wave off as vanity. The authors flag their own limits. The analysis relied on estimates of cardiovascular risk, COVID disrupted data collection, and some participants may have lost weight for other reasons, frailty among them. What explains the rest is open; Colhoun says more research is needed. The article doesn't name a funder. If you live with heart disease and this class has never come up with your cardiologist, here's a reason to raise it.
Madison Czopek, writing for PolitiFact:
The number of 8- to 11-year-olds taking drugs such as Saxenda and Wegovy was 310 times higher in June 2026 than June 2019, new data shows. In that time, 20,282 children ages 8 to 11 had been prescribed GLP-1s, according to a study published in Pediatrics.
Some context. Saxenda and Wegovy are FDA-approved for kids twelve and older. Under twelve is off-label, though the American Academy of Pediatrics guidelines leave room for prescribing as young as eight in certain cases. What's missing is long-term data. A 2025 JAMA Pediatrics review found eighteen randomized trials of GLP-1s in people under eighteen, and nine of them enrolled fewer than fifty patients. Harvard's Dr. Fatima Cody Stanford calls the evidence meaningful but shorter-term than she'd like, especially on growth, puberty and bone health under twelve. And a September study found nearly seventeen percent of kids ten to seventeen who started a GLP-1 had at least one nutritional deficiency or related complication within a year. Vitamin D was most common, then anemia. Dr. Rebecka Peebles of Monte Nido names the bind: losing ten percent of body weight in six months is a malnutrition warning sign in a child, and that's often exactly the goal on these drugs. Those things collide, she says. I chose this medication as an adult with years of history to weigh. Parents are choosing for someone who's still growing. The piece's practical advice: ask for eating-disorder screening before starting, and watch for skipped meals, rigid habits around food, or nonstop exercise. Those are questions for your child's pediatrician before the first dose. Which brings us back to the federal rule from the top. Plans paying for intensive programs for kids six and up is the kind of lifestyle treatment pediatric guidelines call the most evidence-backed. PolitiFact's catch: it isn't widely available.
One ask before we go. If something today left you with a question, or you think we got a detail wrong, write to glp1daily at lantern podcasts dot com. Every note gets read, and corrections make the next episode better.
Each source we quoted is linked in the show notes. That's your Tuesday on GLP-1 Daily, a Lantern Podcast. See you tomorrow.